Entering text into the input field will update the search result below

ZIOPHARM Oncology, Inc. (ZIOP) CEO Laurence Cooper on Q4 2019 Results - Earnings Call Transcript

SA Transcripts profile picture
SA Transcripts

ZIOPHARM Oncology, Inc. (ZIOP) Q4 2019 Results Conference Call March 2, 2020 4:30 PM ET

Company Participants

Chris Taylor - Vice President, Investor Relations and Corporate Communications

Laurence Cooper - Chief Executive Officer

Sath Shukla - Executive Vice President, Chief Financial Officer

David Mauney - President

Conference Call Participants

Yale Jen - Laidlaw & Company

Thomas Flaten - Lake Street Capital

Swayampakula Ramakanth - H.C. Wainwright

Nick Abbott - Wells Fargo


Ladies and gentlemen, thank you for standing by and welcome to the Ziopharm Oncology Fourth Quarter and Year-end 2019 Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] I would now like to hand the conference over to your speaker today, Mr. Chris Taylor, Vice President of Investor Relations. Thank you. Please go ahead.

Chris Taylor

Thank you, operator. Good afternoon and welcome to the Ziopharm Oncology conference call and webcast to review results for the fourth quarter of 2019. This afternoon we filed our 10-K and issued our 2019 year-end results release, both of which are available in the Investors section of our website ziopharm.com. For informational purposes, we have also included in our webcast a set of PowerPoint slides to accompany today's commentary. These slides can also be found on our website in the Investors section.

During this call, the Company will make a number of forward-looking statements, including statements regarding the potential therapeutic candidates in our development pipeline regulatory status, financial information and business trends. Forward-looking statements are subject to numerous risks and uncertainties as described in our 10-K and within other filings that we may make with the SEC from time to time.

Participating on our call today for Ziopharm will be Dr. Laurence Cooper, Chief Executive Officer; Sath Shukla, CFO; and Dr. David Mauney, President. Following commentary from our management team, we will open the call for

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!

About TCRT

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on TCRT

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.